This report was first published by Endpoints News. To see the original version, click here
Gilead Sciences has dedicated around $11 billion so far this year to three acquisitions meant to bolster its pipelines in cancer and immunology. The pharma company, once criticized for making bad deals, hopes it can succeed this time in substantially diversifying from HIV.
Wall Street analysts appear to believe in the purchases. “We are excited by Gilead’s recent string of deals,” TD Cowen analyst Tyler Van Buren wrote Wednesday morning.
您已阅读14%（530字），剩余86%（3265字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。